KATIE GRESHAM: Open Payments
NPI 1003589631 · EVANS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,428 in 113 payments from 22 companies in 2025. Trend: 2023 $2,289 · 2024 $1,979 · 2025 $2,428
Food & beverage: $2,428
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $337 |
| Amgen Inc. | 17 | $336 |
| Lilly USA, LLC | 15 | $296 |
| Corcept Therapeutics | 10 | $255 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $174 |
| Xeris Pharmaceuticals, Inc. | 7 | $135 |
| Ascendis Pharma Endocrinology Inc | 6 | $117 |
| SANOFI-AVENTIS U.S. LLC | 4 | $113 |
| IBSA Pharma Inc. | 4 | $91 |
| Tandem Diabetes Care, Inc. | 4 | $84 |
Products named: Ozempic, MOUNJARO, Korlym, TEPEZZA, Kerendia, TZIELD, Yorvipath, RECORLEV.
Industry payments across GA — which companies pay providers there.
